文献速递神经介入DSA

pEGASUS-HPC支架在脑动脉瘤中的真实世界应用:一项多中心回顾性系列研究结果

Real-world use of the pEGASUS-HPC stent in cerebral aneurysms: results from a multicenter retrospective series.
PubMed 文献 · Neuroradiology · 2025-12-18

这项独立、多中心、回顾性观察研究评估了2022年4月至2024年12月间使用pEGASUS-HPC支架辅助弹簧圈栓塞治疗的98例患者共99个颅内动脉瘤(30个破裂,69个未破裂),共置入130枚支架。支架成功释放率为97%,器械相关死亡率和致残率分别为2%和1%,术后即刻和随访(中位240天)的充分闭塞(Raymond-Roy I-II级)率分别为95%和93%。作者结论认为该支架具有高可行性、安全性和有效性,但需进一步研究评估其表面涂层的影响,尤其是在急诊 settings 中。

要点

  • 支架成功释放率达97%,术后即刻充分闭塞(Raymond-Roy I-II级)率为95%。
  • 随访中位240天时充分闭塞率为93%,器械相关死亡率和致残率分别为2%和1%。
  • 急性与择期病例、单联与双联抗血小板治疗组间的缺血并发症率无显著差异。

核心结论

  • pEGASUS-HPC支架在颅内动脉瘤治疗中显示出高可行性、安全性和有效性;需进一步研究评估其表面涂层的影响,尤其是在急诊 settings 中。

研究设计与样本

  • 独立、多中心、回顾性观察研究,纳入2022年4月至2024年12月间接受pEGASUS-HPC支架辅助弹簧圈栓塞的患者,分析手术结局、并发症(技术性和临床性)及影像随访资料;共98例患者(58例女性,40例男性)、99个动脉瘤(30个破裂,69个未破裂),置入130枚pEGASUS-HPC支架。

诊断标准与关键数值

  • 支架成功释放率为97%;术后即刻充分闭塞(Raymond-Roy I-II级)率为95%,随访(中位240天)时为93%;器械相关死亡率为2%,致残率为1%;急性与择期病例之间、单联与双联抗血小板治疗组之间的缺血并发症率无显著差异。

临床应用与阅片要点

  • 作者结论认为pEGASUS-HPC支架在颅内动脉瘤治疗中显示出高可行性、安全性和有效性;作者指出需进一步研究评估其表面涂层的影响,尤其是在急诊 settings 中。

局限性

  • 原文结论指出需进一步研究评估该支架表面涂层的影响,尤其是在急诊 settings 中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Stent-assisted coiling has revolutionized the treatment of wide-neck intracranial aneurysms. Several technical improvements have since emerged, including enhanced deliverability, low-profile designs, and reduced surface thrombogenicity. This study aimed to assess the real-world feasibility, safety, and efficacy of the pEGASUS-HPC device for intracranial aneurysms.

MATERIALS AND METHODS: This independent, multicenter, retrospective observational study evaluated patients treated with pEGASUS-HPC stent-assisted coiling between April 2022 and December 2024. Data on procedural outcomes, complications (technical and clinical), and imaging follow-up were analyzed.

RESULTS: Ninety-nine aneurysms (30 ruptured (30.3%), 69 unruptured (69.7%)) in 98 patients (58 female (59.2%), 40 male (40.8%) were treated using 130 pEGASUS-HPC stents. The successful deployment rate was 97%. Device-related mortality and morbidity were 2% and 1%, respectively. Ischemic complication rates did not significantly differ between acute and elective cases or between single and dual antiplatelet therapy groups. Adequate occlusion (Raymond-Roy Class I-II) was achieved in 95% immediately post-procedure and 93% at follow-up (median 240 days).

CONCLUSIONS: The pEGASUS-HPC stent shows high feasibility, safety, and effectiveness in the treatment of intracranial aneurysms. Further research is warranted to assess the impact of its surface coating, especially in emergency settings.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Emilio L, Barbante R, Barchetti G, et al. Real-world use of the pEGASUS-HPC stent in cerebral aneurysms: results from a multicenter retrospective series. Neuroradiology. 2025. PMID: 41410872. doi:10.1007/s00234-025-03870-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。